| Literature DB >> 33708932 |
Bin Li1, Yingyi Qin2, Zhiquan Qiu1, Jun Ji3, Xiaoqing Jiang1.
Abstract
BACKGROUND: This cohort study, based on a large sample of extensive hepatectomy cases, aimed to analyze the distribution of hepatectomy-related complications and to develop a predictive model of posthepatectomy liver failure (PHLF).Entities:
Keywords: Major liver resection (MLR); liver failure; nomogram; postoperative complications; predictive model
Year: 2021 PMID: 33708932 PMCID: PMC7944277 DOI: 10.21037/atm-20-5472
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flow chart of 1,441 patients included in the analyses. PHLF, posthepatectomy liver failure; ISGLS, International Research Group of Liver Surgery.
Univariate analyses of demographics and baseline characteristics in the derivation cohort
| Characteristics | Non-PHLF (N=458) | ISGLS-PHLF (N=622) | P value |
|---|---|---|---|
| Gender (female) | 218 (47.60) | 164 (26.37) | <0.0001 |
| Age | 50.50 (43.00, 59.00) | 52.00 (45.00, 60.00) | 0.0249 |
| Blood type | 0.6208 | ||
| A | 154 (33.62) | 193 (31.03) | |
| B | 122 (26.64) | 168 (27.01) | |
| AB | 40 (8.73) | 75 (12.06) | |
| O | 142 (31.00) | 186 (29.90) | |
| BMI | 22.48 (20.55, 24.91) | 22.77 (20.70, 24.90) | 0.4644 |
| Diabetes | 5 (1.09) | 9 (1.45) | 0.6100 |
| Cirrhosis | 70 (15.28) | 132 (21.22) | 0.0134 |
| A long history of heavy drinking | 57 (12.45) | 124 (19.94) | 0.0011 |
| History of chemotherapy before hepatectomy | 0.7305 | ||
| No | 419 (91.48) | 561 (90.19) | |
| TAE | 32 (6.99) | 55 (8.84) | |
| Systemic chemotherapy | 7 (1.53) | 6 (0.96) | |
| Preoperative ascites | 0.6004 | ||
| No | 430 (93.89) | 579 (93.09) | |
| Mild | 28 (6.11) | 43 (6.91) | |
| Moderate to severe | 0 (0.00) | 0 (0.00) | |
| Preoperative serum hemoglobin level (<130 g/L) | 223 (48.69) | 207 (33.28) | <0.0001 |
| Preoperative serum white blood cell count (×109/L) | 5.69 (4.50, 6.93) | 5.39 (4.42, 6.67) | 0.1167 |
| Preoperative serum platelet count (×109/L) | 200.50 (161.00, 256.00) | 181.00 (139.00, 238.00) | <0.0001 |
| Preoperative serum lymphocyte count (×109/L) | 1.53 (1.23, 1.89) | 1.45 (1.15, 1.83) | 0.0316 |
| Preoperative serum neutrophil count (×109/L) | 3.40 (2.57, 4.67) | 3.35 (2.61, 4.36) | 0.2056 |
| Preoperative serum creatinine level (umol/L) | 62.00 (53.00, 73.00) | 65.00 (56.00, 74.00) | 0.0109 |
| Preoperative serum Na+ level (mmol/L) | 142.00 (140.00, 143.00) | 141.00 (140.00, 143.00) | 0.3057 |
| Preoperative serum K+ level (mmol/L) | 4.11 (3.92, 4.35) | 4.12 (3.91, 4.34) | 0.6851 |
| Preoperative serum TBIL level (umol/L) | 11.15 (8.90, 15.40) | 12.95 (9.90, 16.30) | <0.0001 |
| Preoperative serum DBIL level (umol/L) | 4.10 (3.30, 5.90) | 5.00 (3.80, 6.50) | <0.0001 |
| Preoperative serum IBIL level (umol/L) | 7.00 (5.40, 9.30) | 7.80 (5.90, 9.80) | 0.0039 |
| Preoperative serum TBA level (umol/mL) | 0.0009 | ||
| <2.7 | 74 (16.16) | 92 (14.79) | |
| 2.7–5.4 | 159 (34.72) | 157 (25.24) | |
| ≥5.4 | 225 (49.13) | 373 (59.97) | |
| Preoperative serum ALT level (≥50 U/L) | 72 (15.72) | 158 (25.40) | 0.0001 |
| Preoperative serum AST level (≥40 U/L) | 126 (27.51) | 263 (42.28) | <0.0001 |
| Preoperative serum LDH level (≥250 U/L) | 66 (14.41) | 98 (15.76) | 0.5427 |
| Preoperative serum GGT level (U/L) | <0.0001 | ||
| <60 | 181 (39.52) | 170 (27.33) | |
| 60–180 | 187 (40.83) | 254 (40.84) | |
| ≥180 | 90 (19.65) | 198 (31.83) | |
| Preoperative serum TP level (g/L) | 70.40 (66.70, 74.60) | 69.70 (65.90, 73.20) | 0.0175 |
| Preoperative serum ALB level (g/L) | 42.00 (39.20, 44.30) | 41.25 (38.90, 43.60) | 0.0165 |
| Preoperative serum GLB level (g/L) | 28.10 (25.40, 32.00) | 28.10 (25.30, 31.00) | 0.4414 |
| Preoperative serum pALB level (g/L) | 228.00 (170.00, 278.00) | 219.00 (166.00, 268.00) | 0.2304 |
| Preoperative serum fibrinogen concentration (g/L) | 2.87 (2.29, 3.80) | 2.76 (2.24, 3.52) | 0.0467 |
| APTT (s) | 26.70 (24.60, 29.70) | 27.50 (25.10, 30.30) | 0.0074 |
| TT (s) | 19.00 (18.10, 19.90) | 19.30 (18.40, 20.20) | <0.0001 |
| PT (s) | 11.40 (10.80, 12.20) | 11.50 (11.00, 12.30) | 0.0798 |
| INR | 0.95 (0.90, 1.01) | 0.97 (0.92, 1.02) | 0.0461 |
| Child-Pugh grade | 0.9385 | ||
| Grade A | 454 (99.13) | 618 (99.36) | |
| Grade B | 4 (0.87) | 4 (0.64) | |
| HCV-Ab (positive) | 6 (1.31) | 9 (1.45) | 0.8493 |
| HBs-Ag (positive) | 190 (41.48) | 360 (57.88) | <0.0001 |
| HBs-Ab (positive) | 166 (36.24) | 172 (27.65) | 0.0026 |
| HBe-Ag (positive) | 31 (6.77) | 92 (14.79) | <0.0001 |
| HBe-Ab (positive) | 246 (53.71) | 380 (61.09) | 0.0152 |
| HBc-Ab (positive) | 369 (80.57) | 549 (88.26) | 0.0005 |
| Liver segment count excised | <0.0001 | ||
| 3 | 288 (62.88) | 261 (41.96) | |
| 3+ | 45 (9.83) | 50 (8.04) | |
| 4 | 99 (21.62) | 219 (35.21) | |
| 4+ | 18 (3.93) | 64 (10.29) | |
| ≥5 | 8 (1.75) | 28 (4.50) | |
| The segment of liver planned for resection has atrophied (yes) | 124 (27.07) | 124 (19.94) | 0.0058 |
| The planned reserved segment of the liver has developed compensatory hyperplasia (yes) | 21 (4.59) | 32 (5.14) | 0.6740 |
| Pathological diagnostic classification | <0.0001 | ||
| Hepatocellular carcinoma | 172 (37.55) | 363 (58.36) | |
| Intrahepatic cholangiocarcinoma | 106 (23.14) | 98 (15.76) | |
| Hepatic hemangioma | 24 (5.24) | 24 (3.86) | |
| Intrahepatic cholelithiasis | 115 (25.11) | 98 (15.76) | |
| Metastatic hepatoma | 11 (2.40) | 12 (1.93) | |
| Other space-occupying diseases of the liver and biliary system | 30 (6.55) | 27 (4.34) |
Data are shown as n (%) or median (range). Na+, sodium; K+, potassium; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TBA, total bile acid; ALT, alanine aminotransferase; AST, aspartic acid transferase; LDH, lactate dehydrogenase; GGT, gamma-glutamyltransferase; TP, total protein; ALB, albumin; GLB, globulin; pALB, prealbumin; APTT, activated partial thromboplastin; TT, thrombin time; PT, prothrombin time; INR, international standardized ratio; HCV-Ab, hepatitis C antibody; HBs-Ag, hepatitis B surface antigen; HBs-Ab, hepatitis B surface antibody; HBe-Ag, hepatitis B e antigen; HBe-Ab, hepatitis B e antibody; HBc-Ab, hepatitis B core antibody.
Final prediction model of posthepatectomy liver failure in the derivation cohort
| Variable | Parameter estimate | Adjusted OR (95% CI) | P value |
|---|---|---|---|
| Gender | |||
| Male | – | Ref | |
| Female | −1.0763 | 0.341 (0.239–0.486) | <0.0001 |
| Age | 0.0291 | 1.030 (1.017–1.043) | <0.0001 |
| Preoperative serum platelet count (×109/L) | −0.0020 | 0.998 (0.996–1.000) | 0.0277 |
| Preoperative serum creatinine level (umol/L) | −0.0143 | 0.986 (0.974–0.997) | 0.0153 |
| Preoperative serum GGT level (U/L) | |||
| <60 | – | Ref | |
| 60–180 | 0.0934 | 1.098 (0.799–1.508) | 0.5640 |
| ≥180 | 0.5418 | 1.719 (1.176–2.512) | 0.0051 |
| Preoperative serum fibrinogen concentration (g/L) | −0.2237 | 0.800 (0.685–0.934) | 0.0047 |
| TT (s) | 0.1074 | 1.113 (1.014–1.223) | 0.0251 |
| HBe-Ag | |||
| Negative | – | Ref | |
| Positive | 0.6348 | 1.887 (1.184–3.007) | 0.0076 |
| Liver segment count excised | |||
| 3 | – | Ref | |
| 3+ | 0.2658 | 1.304 (0.814–2.090) | 0.2690 |
| 4 | 0.8440 | 2.326 (1.696–3.189) | <0.0001 |
| 4+ | 1.3119 | 3.713 (2.099–6.568) | <0.0001 |
| ≥5 | 1.4121 | 4.105 (1.768–9.531) | 0.0010 |
The criterion for variables in included in multivariable logistic regression is: P value of univariate analysis ≤0.20. The backward stepwise selection method was used in multivariable logistic regression (αsls=0.05). OR, odds ratio; GGT, gamma-glutamyltransferase; TT, thrombin time; HBe-Ag, hepatitis B e antigen.
Figure 2Nomogram for the prediction model of posthepatectomy liver failure. GGT, gamma-glutamyltransferase; TT, thrombin time.
Performance for prediction model of posthepatectomy liver failure
| Performance index | Derivation cohort | Validation cohort | Internal validation-corrected index (95% CI)* | |
|---|---|---|---|---|
| Derivation cohort | Validation cohort | |||
| AUC (95% CI) | 0.726 (0.696–0.760) | 0.717 (0.663–0.770) | 0.711 (0.682, 0.739) | 0.718 (0.666, 0.765) |
| Intercept | 0.000 | 0.000 | 0.021 (−0.113, 0.154) | −0.012 (−0.286, 0.218) |
| Slope | 1.000 | 1.000 | 0.92 (0.783, 1.067) | 1.019 (0.76, 1.348) |
| Brier scaled | 0.207 | 0.207 | 0.213 (0.203, 0.224) | 0.209 (0.194, 0.229) |
| R2 | 0.202 | 0.180 | 0.176 (0.124, 0.223) | 0.18 (0.088, 0.254) |
*, the 1,000 bootstrap resampling method was implied to perform internal validation in the derivation and validation cohort. AUC, area under receiver operating characteristic curve.
Receiver operating characteristic analysis of prediction model for predicting the PHLF grade in total cohort
| Performance index | Grade ≥ A | Grade ≥ B | Grade ≥ C |
|---|---|---|---|
| ROC | 0.723 (0.697–0.750) | 0.792 (0.735–0.850) | 0.821 (0.720–0.922) |
| Cut-off* | 172.63 | 188.57 | 209.02 |
| Specificity | 0.741 (0.706–0.777) | 0.702 (0.679–0.726) | 0.848 (0.830–0.867) |
| Sensitivity | 0.604 (0.572–0.638) | 0.778 (0.667–0.873) | 0.714 (0.524–0.905) |
| Accuracy | 0.661 (0.637–0.686) | 0.705 (0.683–0.728) | 0.847 (0.829–0.865) |
| Negative predictive value | 0.573 (0.550–0.597) | 0.986 (0.979–0.992) | 0.995 (0.992–0.998) |
| Positive predictive value | 0.765 (0.738–0.792) | 0.107 (0.092–0.122) | 0.066 (0.047–0.083) |
*, the optimal cut-off value of total points of prediction model were selected based on the Youden index.